All In Biotech

Drug Trial Radar · NCT05835180

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Last checked: Nov 19, 2026Latest source record: Dec 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

May 1, 2023

Primary completion

Dec 18, 2023

Study completion Dec 18, 2023

Sponsor

Lead sponsor
Sagimet Biosciences Inc.Industry
Sponsor type
Industry
First posted
Apr 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this phase 1 study is to assess the pharmacokinetics, safety and tolerability following multiple oral doses of TVB-2640 in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.

Conditions

  • Non-alcoholic Steatohepatitis
  • Hepatic Impairment
  • Cirrhosis

Interventions

  • TVB-2640 - 50 mgDrug

    TVB-2640 -50 mg administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total TVB-2640 plasma concentration-time (AUC) at steady stateTime frame: Day 4
  2. Unbound TVB-2640 plasma concentration-time (AUC) at steady stateTime frame: Day 4
  3. Maximum plasma concentration (Cmax) for total TVB-2640 at steady stateTime frame: Day 4
  4. Maximum plasma concentration (Cmax) for unbound TVB-2640 at steady stateTime frame: Day 4
  5. incidence and severity of AEsTime frame: Screening to Day 7

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Thomas C. Marbury

    Orlando, Florida

  • Eric J. Lawitz, MD

    San Antonio, Texas

  • Geza Lakner

    Kistarcsa, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.